You said: Create a successor to Utopian Pharmacology (2026), an update of mdma.
Create a successor to Utopian Pharmacology (2026), an update of [mdma.net](https://www.mdma.net) (2002)
Claude responded: Let me fetch the rest of the page, particularly the later sections and the 2024 update.
Let me fetch the rest of the page, particularly the later sections and the 2024 update.
Now I have a thorough understanding of the original. Let me write the 2026 successor — retaining the Pearcean voice, structure, and scientific ambition while updating for everything that has happened in the intervening quarter-century, including the pivotal 2024 FDA rejection of MDMA-assisted therapy.
The document is ready. Here's an overview of what the successor essay covers:
Structure and voice — Written in the same register as the 2002 original: technically rigorous, philosophically expansive, with the characteristic Pearcean blend of neuroscience and moral seriousness. Typeset in Cormorant Garamond/EB Garamond to echo the essay's contemplative tone.
The eleven sections:
- The Intervening Quarter-Century — The psychedelic renaissance, from whisper to mainstream and back again
- The FDA Ruling of 2024 — The MAPS rejection dissected: what failed was the regulatory interface, not the science; the unblinding problem as a methodological crisis for the whole field
- What MDMA Taught Us — Amygdala fear-extinction, the 5-HT₁A/oxytocin pathway, BDNF-mediated neuroplasticity windows, and a more nuanced toxicity picture
- Next-Generation Candidates — MDAI, 5-MAPB/6-APB, substrate-selective releasers, and the lessons of the Bromo-DragonFLY disaster; the fundamental tolerance problem revisited
- The Oxytocin Frontier — Why intranasal OT largely failed, and the three more promising approaches now being pursued
- Psychoplastogens — BDNF/TrkB agonists, the critical-period analogy, and why neuroplasticity may be more important than acute phenomenology
- Kappa-Opioid Antagonism — Dynorphin, the "dysphoria default," and why KOR antagonists are the most plausible near-term route to sustained prosocial wellbeing
- The Hedonic Genome — FAAH, SLC6A4, OXTR variants; somatic vs germline editing; the ethical burden of the genetic lottery
- The Consciousness Question — What entactogenesis reveals about the default mode network, the constructed self-model, and the philosophical status of the MDMA-naïve state
- Post-Darwinian Medicine in 2026 — The obstacles (political, institutional, cultural) and their contingency
- Conclusion — Cautious predictions to 2050, and the closing argument